Display options
Cite
Scheithauer BW, Kovacs KT, Stefaneanu L, et al. The Pituitary in Gigantism. Endocr Pathol. 1995;6(3):173-187doi: 10.1007/BF02739881.
Scheithauer, B. W., Kovacs, K. T., Stefaneanu, L., Horvath, E., Kane, L. A., Young, W. F., Lloyd, R. V., Randall, R. V., & Davis, D. H. (1995). The Pituitary in Gigantism. Endocrine pathology, 6(3), 173-187. https://doi.org/10.1007/BF02739881
Scheithauer, Bernd W., et al. "The Pituitary in Gigantism." Endocrine pathology vol. 6,3 (1995): 173-187. doi: https://doi.org/10.1007/BF02739881
Scheithauer BW, Kovacs KT, Stefaneanu L, Horvath E, Kane LA, Young WF, Lloyd RV, Randall RV, Davis DH. The Pituitary in Gigantism. Endocr Pathol. 1995;6(3):173-187. doi: 10.1007/BF02739881. PMID: 12114738.
Copy Download .nbib Format: NLM
Share it on

Endocr Pathol. 1995;6(3):173-187. doi: 10.1007/BF02739881.

The Pituitary in Gigantism.

Endocrine pathology

Bernd W. Scheithauer, Kalman T. Kovacs, Lucia Stefaneanu, Eva Horvath, Laurie A. Kane, William F. Young, Ricardo V. Lloyd, Raymond V. Randall, Dudley H. Davis

Affiliations

  1. MD, PhD.

PMID: 12114738 DOI: 10.1007/BF02739881

Abstract

To compare the pituitary pathology of gigantism to that of acromegaly, 19 surgically resected lesions were studied from 10 males and 9 females, ages 13-49 (mean, 19 yr) with excessive height (>/=95th percentile), onset of disease prior to puberty, elevated growth hormone (GH) levels despite glucose suppression, and a pathologically confirmed GH-producing pituitary mass. One patient had MEN-I. The lesions included 18 adenomas and 1 case of pure hyperplasia. The median, mean, and range of serum GH and prolactin (PRL) levels were 64, 235, 5-1000 ng/mL and 47, 146, 29-770 ng/mL, respectively. Of the 8 adenoma specimens accompanied by nontumoral pituitary (i.e., tissue wherein the presence of hyperplasia was assessable), 3 (37%) demonstrated both. Of the 18 tumors, 78% were macroadenomas and 22% were grossly invasive; their immunophenotypes included GH (5%), GH and PRL (19%), and GHPRL and a glycoprotein hormone, usually TSH and/or a-subunit (76%). Of the 10 adenoma-containing lesions subject to electron microscopy (EM), 2 consisted of GH cells alone; 2 of mammosomatotroph (MS) cells alone; 1 of GH and MS cells; 1 of GH and PRL cells; 2 of GH, PRL, and MS cells; 1 of GH, PRL, and glycoprotein cells; and 1 was a subtype 3 adenoma. Ultrastructurally, GH cells and/or MS cells predominated in these lesions. Immuno-EM of one CH and PRL cell and of one GH-PR-MS tumor showed GH and PRL to be present not only in single cells but within the same granules. Nine of 12 adenoma-associated lesions subject to combined in situ hybridization (ISH) and immunostaining showed double labeling for PRL (or GH) mRNA and for GH (or PRL), respectively, features indicating MS differentiation. In the 4 lesions exhibiting hyperplasia, either alone (1) or in association with adenoma (3), EM showed MS cells in 3, and immuno-EM as well as combined immunohistochemistry and ISH showed double labeling for GH and PRL in both of the 2 cases studied. In summary, although in terms of their tinctorial characteristics and tumor size, the lesions of giants resemble those of acromegalics, those of the former are less often invasive and glycoprotein hormone containing, and more often contain ultrastructurally distinctive MS cells. The high frequency of adenoma with hyperplasia (37%) and the occurrence of hyperplasia alone (6%) is of particular notice since this finding is rare in patients with acromegaly. Hyperplasia is, however, seen in ectopic GH-releasing hormone production and the McCune-Albright syndrome. We conclude that the presence of MS is not rare in the pituitary lesions of patients with gigantism. Their presence may be a reflection of either hypothalamic dysfunction or of an intrinsic abnormality of pituitary cells,

References

  1. J Clin Endocrinol Metab. 1986 Jun;62(6):1093-100 - PubMed
  2. Endocr J. 1993 Feb;40(1):133-9 - PubMed
  3. N Engl J Med. 1990 Apr 5;322(14):966-77 - PubMed
  4. Clin Endocrinol Metab. 1986 Aug;15(3):655-81 - PubMed
  5. Cell. 1992 Aug 21;70(4):527-30 - PubMed
  6. Endocr Rev. 1988 Aug;9(3):357-73 - PubMed
  7. Am J Anat. 1989 Jun-Jul;185(2-3):236-43 - PubMed
  8. Virchows Arch A Pathol Anat Histopathol. 1983;398(3):277-89 - PubMed
  9. Acta Neuropathol. 1986;71(1-2):76-82 - PubMed
  10. Semin Diagn Pathol. 1986 Feb;3(1):18-33 - PubMed
  11. Surg Neurol. 1983 Dec;20(6):498-503 - PubMed
  12. J Clin Endocrinol Metab. 1988 Jun;66(6):1103-10 - PubMed
  13. Am J Pathol. 1989 Feb;134(2):345-53 - PubMed
  14. J Electron Microsc Tech. 1988 Apr;8(4):401-32 - PubMed
  15. Endocrinology. 1989 Nov;125(5):2710-8 - PubMed
  16. Lab Invest. 1993 Nov;69(5):570-5 - PubMed
  17. Virchows Arch A Pathol Anat Histopathol. 1993;422(3):193-201 - PubMed
  18. J Neurosurg. 1993 Jul;79(1):70-5 - PubMed
  19. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6854-7 - PubMed
  20. N Engl J Med. 1990 Aug 2;323(5):322-7 - PubMed
  21. Am J Pathol. 1989 Mar;134(3):605-13 - PubMed
  22. Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62(5):291-6 - PubMed
  23. J Clin Endocrinol Metab. 1994 Dec;79(6):1706-15 - PubMed
  24. Endocrinol Metab Clin North Am. 1987 Sep;16(3):529-51 - PubMed
  25. Am J Pathol. 1992 Oct;141(4):895-906 - PubMed
  26. J Clin Endocrinol Metab. 1993 Jan;76(1):216-22 - PubMed
  27. Trends Endocrinol Metab. 1989 Nov-Dec;1(2):104-7 - PubMed
  28. Semin Diagn Pathol. 1986 Feb;3(1):69-82 - PubMed
  29. Endocrinology. 1985 Feb;116(2):734-7 - PubMed
  30. J Clin Endocrinol Metab. 1993 Nov;77(5):1275-80 - PubMed
  31. Neurochirurgie. 1973 May;19(2):Suppl 2:117-62 - PubMed
  32. J Histochem Cytochem. 1982 Jan;30(1):81-5 - PubMed
  33. Endocr Rev. 1991 Nov;12(4):337-55 - PubMed
  34. Lab Invest. 1990 Oct;63(4):511-20 - PubMed
  35. J Clin Endocrinol Metab. 1990 Dec;71(6):1416-20 - PubMed
  36. Endocrinology. 1992 Nov;131(5):2083-9 - PubMed
  37. Virchows Arch A Pathol Anat Histopathol. 1984;403(1):77-86 - PubMed
  38. Mayo Clin Proc. 1990 Apr;65(4):461-74 - PubMed

Publication Types